Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions

Vitiligo

Interventions

DRUG

Apremilast

Apremilast 30 mg orally, twice daily. (oral tablet)

PROCEDURE

NB-UVB phototherapy

treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York